文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

COVID-19患者接受静脉-静脉体外膜氧合期间获得性血管性血友病综合征与去氨加压素抵抗:一项前瞻性观察研究

Acquired von Willebrand Syndrome and Desmopressin Resistance During Venovenous Extracorporeal Membrane Oxygenation in Patients With COVID-19: A Prospective Observational Study.
PubMed 文献 · Crit Care Med · 2022-02-18
一句话结论COVID-19相关ARDS患者启动vvECMO后数小时内即发生获得性血管性血友病综合征(AVWS),去氨加压素无效,出血时作者建议优先使用含血管性血友病因子的浓缩制剂。

该前瞻性观察研究在三级医疗中心ICU纳入27例需vvECMO的COVID-19相关ARDS患者,在vvECMO前、中、后行全面血管性血友病因子(vWF)分析(包括SDS-PAGE)。vvECMO前vWF抗原、胶原结合能力、活性和因子VIII活性均显著升高,高分子量vWF多聚体仅边缘性降低;启动vvECMO后数小时内上述指标均下降且高分子量vWF多聚体变为不可测,停用vvECMO后3-38小时内全部完全恢复。vWF活性/vWF抗原比值下降与高分子量vWF多聚体缺失相关,可作为AVWS的筛查试验。12例AVWS患者中去氨加压素治疗未影响vWF参数。

要点

  • 27例COVID-19相关ARDS患者启动vvECMO后数小时内高分子量vWF多聚体变为不可测,全部vWF指标下降。
  • 停用vvECMO后3-38小时内所有vWF变量完全恢复至基线水平。
  • vWF活性/vWF抗原比值下降与高分子量vWF多聚体缺失相关,可作为AVWS的筛查试验。
  • 12例AVWS患者中去氨加压素治疗未影响vWF参数,作者认为vvECMO相关AVWS出血时优先使用含vWF的浓缩制剂。

适用人群与场景

  • 三级医疗中心ICU中连续纳入的27例需vvECMO的COVID-19相关急性呼吸窘迫综合征(ARDS)患者;平均年龄53岁(范围23-73岁),70%为男性,均有多种合并症。

诊断标准与关键阈值

  • AVWS诊断依据全面vWF分析(包括十二烷基硫酸钠-聚丙烯酰胺凝胶电泳)显示高分子量vWF多聚体缺失;vWF活性/vWF抗原比值下降与高分子量vWF多聚体缺失相关,可作为AVWS的筛查试验。

处置流程与药物剂量

  • 在12例AVWS患者中评估去氨加压素治疗效果,去氨加压素未影响vWF参数。
  • 作者认为,vvECMO相关AVWS出血时优先使用含vWF的浓缩制剂治疗。

研究设计与关键结果

  • 前瞻性观察研究,纳入27例需vvECMO的COVID-19相关ARDS患者,在vvECMO前、中、后行全面vWF分析(包括SDS-PAGE);12例AVWS患者亚组评估去氨加压素疗效。
  • vvECMO前vWF抗原平均546%(SD 282)、vWF胶原结合能力平均469%(SD 271)、vWF活性平均383%(SD 132)、因子VIII活性平均302%(SD 106),高分子量vWF多聚体仅边缘性降低。
  • 启动vvECMO后数小时内上述所有变量下降,高分子量vWF多聚体变为不可测。
  • 停用vvECMO后3-38小时内所有变量完全恢复。
  • vvECMO期间vWF活性/vWF抗原比值下降与高分子量vWF多聚体缺失相关。
  • 去氨加压素未影响vWF参数。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对COVID-19相关ARDS接受vvECMO的患者,应认识到启动vvECMO后数小时内即可发生AVWS,vWF活性/vWF抗原比值可作为筛查试验。
  • 作者认为,vvECMO相关AVWS出血时去氨加压素无效,优先使用含vWF的浓缩制剂治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Although COVID-19 is associated with high von Willebrand factor (vWF) parameters promoting thrombosis, venovenous extracorporeal membrane oxygenation (vvECMO) is associated with the development of acquired von Willebrand syndrome (AVWS) promoting bleeding. This study was designed to assess both the incidence and severity of AVWS in COVID-19 patients undergoing vvECMO, and the benefit of comprehensive vWF analyses.

DESIGN: Prospective observational study.

SETTING: ICU at a tertiary-care center.

PATIENTS: Twenty-seven consecutive COVID-19 patients with acute respiratory distress syndrome (ARDS) requiring vvECMO.

MEASUREMENTS AND MAIN RESULTS: Comprehensive vWF analyses (including sodium dodecyl-sulfate polyacrylamide gel electrophoresis) were performed before, during, and after vvECMO. In a subgroup of 12 patients with AVWS, effectiveness of treatment with desmopressin was assessed. The patients' mean age was 53 years (range, 23-73), 70% were male, and all had various comorbidities. Following markedly elevated vwf antigen (vWF: Ag; mean, 546% ( sd , 282]), vWF collagen binding capacity (mean, 469% [ sd , 271]), vWF activity (vWF:A; mean, 383% [ sd , 132]), and factor VIII activity (mean, 302% [ sd , 106]), and only borderline decreases in high-molecular-weight (HMW) vWF multimers before vvECMO, all of these variables decreased and HMW vWF multimers became undetectable within hours following initiation of vvECMO. All variables fully recovered within 3-38 hours after discontinuation of vvECMO. During vvECMO, decreases in the vWF:A/vWF:Ag ratio correlated with absent HMW vWF multimers. Desmopressin did not affect vWF parameters.

CONCLUSIONS: In patients with COVID-19-associated ARDS, AVWS developed soon after initiation of vvECMO. The vWF:A/vWF:Ag ratio was a suitable screening test for AVWS. As desmopressin was ineffective, bleeding during vvECMO-associated AVWS should preferably be treated with concentrates containing vWF.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kalbhenn J, Glonnegger H, Büchsel M, et al. Acquired von Willebrand Syndrome and Desmopressin Resistance During Venovenous Extracorporeal Membrane Oxygenation in Patients With COVID-19: A Prospective Observational Study. Crit Care Med. 2022. PMID: 35234414. doi:10.1097/CCM.0000000000005467

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。